DV
Dividend Vision

CRDL — Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc Class A (CRDL)

Total return is -51.9% over the past 7.6 years, 285.2 points behind SPY at 233.3%. Its deepest 1-year drawdown was 39.1%.

CRDL is an equity fund that tracks Cardiol Therapeutics Inc Class A shares. As a single-stock fund with no distribution rate or expense ratio data available, it functions as a direct equity holding rather than a traditional dividend-focused ETF. This fund structure appeals to investors seeking exposure to a specific biopharmaceutical company rather than those primarily focused on regular income distributions.

CRDL key facts

Asset type
Stock
Asset class
Equity
Inception date
01/15/2019
Last close
$1.80
Market cap
$139,479,408
Average volume
1725500.0
Beta
0.507
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.27